Long-term effect of efavirenz autoinduction on plasma/peripheral blood mononuclear cell drug exposure and CD4 count is influenced by UGT2B7 and CYP2B6 genotypes among HIV patients

Journal of Antimicrobial Chemotherapy

Volumn 66, Issue 10, 2011, Pages 2350-2361

  Habtewold, Abiy ^a,b   Amogne, Wondwossen ^a,b   Makonnen, Eyasu ^b   Yimer, Getnet ^a,b   Riedel, Klaus Dieter ^c   Ueda, Nobuhisa ^a   Worku, Alemayehu ^d   Haefeli, Walter Emil ^c   Lindquist, Lars ^a   Aderaye, Getachew ^b   Burhenne, Jürgen ^c   Aklillu, Eleni ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b ADDIS ABABA UNIVERSITY   (Ethiopia)

^c UNIVERSITY OF HEIDELBERG   (Germany)

^d ADDIS ABABA UNIVERSITY   (Ethiopia)

Author keywords

CYP3A5; Ethiopians; HAART; Induction

Indexed keywords

8 HYDROXYEFAVIRENZ; CYTOCHROME P450 2B6; CYTOCHROME P450 3A5; DRUG METABOLITE; EFAVIRENZ; EFAVIRENZ PLUS LAMIVUDINE PLUS ZIDOVUDINE; GLUCURONOSYLTRANSFERASE 2B7; LAMIVUDINE; MULTIDRUG RESISTANCE PROTEIN 1; STAVUDINE; STAVUDINE PLUS LAMIVUDINE PLUS EFAVIRENZ; TENOFOVIR; TENOFOVIR PLUS LAMIVUDINE PLUS EFAVIRENZ; UNCLASSIFIED DRUG; ZIDOVUDINE;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG EXPOSURE; DRUG METABOLISM; FEMALE; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HETEROZYGOTE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PERIPHERAL BLOOD MONONUCLEAR CELL; PREDICTIVE VALUE; SEX DIFFERENCE; TREATMENT DURATION;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; ARYL HYDROCARBON HYDROXYLASES; BENZOXAZINES; CD4 LYMPHOCYTE COUNT; ENZYME INDUCTION; FEMALE; GENOTYPE; GLUCURONOSYLTRANSFERASE; HIV INFECTIONS; HIV-1; HUMANS; LEUKOCYTES, MONONUCLEAR; MALE; OXIDOREDUCTASES, N-DEMETHYLATING; SEX FACTORS;

EID: 80052905460     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkr304     Document Type: Article

References (54)

1. Best BM, Goicoechea M. Efavirenz-still first-line king? Expert Opin Drug Metab Toxicol 2008; 4: 965-72.
2. Langmann P, Weissbrich B, Desch S et al. Efavirenz plasma levels for the prediction of treatment failure in heavily pretreated HIV-1 infected patients. Eur J Med Res 2002; 7: 309-14.
3. Stahle L, Moberg L, Svensson JO et al. Efavirenz plasma concentrations in HIV-infected patients: inter- and intraindividual variability and clinical effects. Ther Drug Monit 2004; 26: 267-70.
4. Mocroft A, Ruiz L, Reiss P et al. Virological rebound after suppression on highly active antiretroviral therapy. AIDS 2003; 17: 1741-51.
5. Paredes R, Mocroft A, Kirk O et al. Predictors of virological success and ensuing failure in HIV-positive patients starting highly active antiretroviral therapy in Europe: results from the EuroSIDA study. Arch Intern Med 2000; 160: 1123-32.
6. Smith CJ, Phillips AN, Dauer B et al. Factors associated with viral rebound among highly treatment-experienced HIV-positive patients who have achieved viral suppression. HIV Med 2009; 10: 19-27.
7. Brundage RC, Yong FH, Fenton T et al. Intrapatient variability of efavirenz concentrations as a predictor of virologic response to antiretroviral therapy. Antimicrob Agents Chemother 2004; 48: 979-84.
8. Pfister M, Labbe L, Hammer SM et al. Population pharmacokinetics and pharmacodynamics of efavirenz, nelfinavir, and indinavir: Adult AIDS Clinical Trial Group Study 398. Antimicrob Agents Chemother 2003; 47: 130-7.
9. Marzolini C, Telenti A, Decosterd LA et al. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients. AIDS 2001; 15: 71-5.
10. Maggiolo F, Ravasio L, Ripamonti D et al. Similar adherence rates favor different virologic outcomes for patients treated with nonnucleoside analogues or protease inhibitors. Clin Infect Dis 2005; 40: 158-63.
11. DuPont-Pharma Laboratories. Sustiva. Allerg Immunol (Paris) 1998; 30: 302.
12. Barrett JS, Joshi AS, Chai M et al. Population pharmacokinetic meta-analysis with efavirenz. Int J Clin Pharmacol Ther 2002; 40: 507-19.
13. Ward BA, Gorski JC, Jones DR et al. The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity. J Pharmacol Exp Ther 2003; 306: 287-300.
14. Ogburn ET, Jones DR, Masters AR et al. Efavirenz primary and secondary metabolism in vitro and in vivo: identification of novel metabolic pathways and cytochrome P450 2A6 as the principal catalyst of efavirenz 7-hydroxylation. Drug Metab Dispos 2010; 38: 1218-29.
15. Belanger AS, Caron P, Harvey M et al. Glucuronidation of the antiretroviral drug efavirenz by UGT2B7 and an in vitro investigation of drug-drug interaction with zidovudine. Drug Metab Dispos 2009; 37: 1793-6.
16. Cho DY, Ogburn ET, Jones D et al. Contribution of N-glucuronidation to efavirenz elimination in vivo in the basal and rifampin-induced metabolism of efavirenz. Antimicrob Agents Chemother 2011; 55: 1504-9.
17. Mukonzo JK, Roshammar D, Waako P et al. A novel polymorphism in ABCB1 gene, CYP2B6*6 and sex predict single-dose efavirenz population pharmacokinetics in Ugandans. Br J Clin Pharmacol 2009; 68: 690-9.
18. Elens L, Vandercam B, Yombi JC et al. Influence of host genetic factors on efavirenz plasma and intracellular pharmacokinetics in HIV-1-infected patients. Pharmacogenomics 2010; 11: 1223-34.
19. Zhu M, Kaul S, Nandy P et al. A model-based approach to characterize efavirenz autoinduction and concurrent enzyme induction with carbamazepine. Antimicrob Agents Chemother 2009; 53: 2346-53.
20. Robertson SM, Maldarelli F, Natarajan V et al. Efavirenz induces CYP2B6-mediated hydroxylation of bupropion in healthy subjects. J Acquir Immune Defic Syndr 2008; 49: 513-9.
21. Mouly S, Lown KS, Kornhauser D et al. Hepatic but not intestinal CYP3A4 displays dose-dependent induction by efavirenz in humans. Clin Pharmacol Ther 2002; 72: 1-9.
22. Efavirenz (Sustiva). Res Initiat Treat Action 2000; 6: 22-3.
23. Ngaimisi E, Mugusi S, Minzi OM et al. Long-term efavirenz autoinduction and its effect on plasma exposure in HIV patients. Clin Pharmacol Ther 2010; 88: 676-84.
24. Almond LM, Hoggard PG, Edirisinghe D et al. Intracellular and plasma pharmacokinetics of efavirenz in HIV-infected individuals. J Antimicrob Chemother 2005; 56: 738-44.
25. Burger D, van der Heiden I, la Porte C et al. Interpatient variability in the pharmacokinetics of the HIV non-nucleoside reverse transcriptase inhibitor efavirenz: the effect of gender, race, and CYP2B6 polymorphism. Br J Clin Pharmacol 2006; 61: 148-54.
26. Desta Z, Saussele T, Ward B et al. Impact of CYP2B6 polymorphism on hepatic efavirenz metabolism in vitro. Pharmacogenomics 2007; 8: 547-58.
27. Faucette SR, Zhang TC, Moore R et al. Relative activation of human pregnane X receptor versus constitutive androstane receptor defines distinct classes of CYP2B6 and CYP3A4 inducers. J Pharmacol Exp Ther 2007; 320: 72-80.
28. Ehrhardt M, Mock M, Haefeli WE et al. Monitoring of lopinavir and ritonavir in peripheral blood mononuclear cells, plasma, and ultrafiltrate using a selective and highly sensitive LC/MS/MS assay. J Chromatogr B Analyt Technol Biomed Life Sci 2007; 850: 249-58.
29. Burhenne J, Matthee AK, Pasakova I et al. No evidence for induction of ABC transporters in peripheral blood mononuclear cells in humans after 14 days of efavirenz treatment. Antimicrob Agents Chemother 2010; 54: 4185-91.
30. Aklillu E, Dandara C, Bertilsson L et al. Pharmacogenetics of cytochrome P450s in African populations: clinical and molecular evolutionary implications. In: Suarez-Kurtz G, ed. Pharmacogenomics in Admixed Populations. Austin, TX: Landes Bioscience, 2007; 99-119.
31. Gebeyehu E, Engidawork E, Bijnsdorp A et al. Sex and CYP3A5 genotype influence total CYP3A activity: high CYP3A activity and a unique distribution of CYP3A5 variant alleles in Ethiopians. Pharmacogenomics J 2011; 11: 130-7.
32. Rotger M, Tegude H, Colombo S et al. Predictive value of known and novel alleles of CYP2B6 for efavirenz plasma concentrations in HIV-infected individuals. Clin Pharmacol Ther 2007; 81: 557-66.
33. Nyakutira C, Roshammar D, Chigutsa E et al. High prevalence of the CYP2B6 516G→T(*6) variant and effect on the population pharmacokinetics of efavirenz in HIV/AIDS outpatients in Zimbabwe. Eur J Clin Pharmacol 2008; 64: 357-65.
34. Arab-Alameddine M, Di Iulio J, Buclin T et al. Pharmacogenetics-based population pharmacokinetic analysis of efavirenz in HIV-1-infected individuals. Clin Pharmacol Ther 2009; 85: 485-94.
35. Mutlib AE, Chen H, Nemeth GA et al. Identification and characterization of efavirenz metabolites by liquid chromatography/mass spectrometry and high field NMR: species differences in the metabolism of efavirenz. Drug Metab Dispos 1999; 27: 1319-33.
36. di Iulio J, Fayet A, Arab-Alameddine M et al. In vivo analysis of efavirenz metabolism in individuals with impaired CYP2A6 function. Pharmacogenet Genomics 2009; 19: 300-9.
37. Kwara A, Lartey M, Sagoe KW et al. CYP2B6, CYP2A6 and UGT2B7 genetic polymorphisms are predictors of efavirenz mid-dose concentration in HIV-infected patients. AIDS 2009; 23: 2101-6.
38. Bae SK, Jeong YJ, Lee C et al. Identification of human UGT isoforms responsible for glucuronidation of efavirenz and its three hydroxy metabolites. Xenobiotica 2011; 41: 437-44.
39. Tang C, Lin JH, Lu AY. Metabolism-based drug-drug interactions: what determines individual variability in cytochrome P450 induction? Drug Metab Dispos 2005; 33: 603-13.
40. Cohen K, Grant A, Dandara C et al. Effect of rifampicin-based antitubercular therapy and the cytochrome P450 2B6 516G.T polymorphism on efavirenz concentrations in adults in South Africa. Antivir Ther 2009; 14: 687-95.
41. Ren Y, Nuttall JJ, Eley BS et al. Effect of rifampicin on efavirenz pharmacokinetics in HIV-infected children with tuberculosis. J Acquir Immune Defic Syndr 2009; 50: 439-43.
42. Ramachandran G, Hemanth Kumar AK, Rajasekaran S et al. CYP2B6 G516T polymorphism but not rifampin coadministration influences steady-state pharmacokinetics of efavirenz in human immunodeficiency virus-infected patients in South India. Antimicrob Agents Chemother 2009; 53: 863-8.
43. Ngaimisi E, Mugusi S, Minzi OM et al. Effect of rifampicin and CYP2B6 genotype on long-term efavirenz autoinduction and plasma exposure in HIV patients with and without tuberculosis. Clin Pharmacol Ther 2011; in press.
44. Bumpus NN, Kent UM, Hollenberg PF. Metabolism of efavirenz and 8-hydroxyefavirenz by P450 2B6 leads to inactivation by two distinct mechanisms. J Pharmacol Exp Ther 2006; 318: 345-51.
45. VandenBrink BM, Isoherranen N. The role of metabolites in predicting drug-drug interactions: focus on irreversible cytochrome P450 inhibition. Curr Opin Drug Discov Devel 2010; 13: 66-77.
46. Cabrera SE, Santos D, Valverde MP et al. Influence of the cytochrome P450 2B6 genotype on population pharmacokinetics of efavirenz in human immunodeficiency virus patients. Antimicrob Agents Chemother 2009; 53: 2791-8.
47. Csajka C, Marzolini C, Fattinger K et al. Population pharmacokinetics and effects of efavirenz in patients with human immunodeficiency virus infection. Clin Pharmacol Ther 2003; 73: 20-30.
48. Kappelhoff BS, van Leth F, MacGregor TR et al. Nevirapine and efavirenz pharmacokinetics and covariate analysis in the 2NN study. Antivir Ther 2005; 10: 145-55.
49. Haas DW, Ribaudo HJ, Kim RB et al. Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study. AIDS 2004; 18: 2391-400.
50. Holthe M, Rakvag TN, Klepstad P et al. Sequence variations in the UDP-glucuronosyltransferase 2B7 (UGT2B7) gene: identification of 10 novel single nucleotide polymorphisms (SNPs) and analysis of their relevance to morphine glucuronidation in cancer patients. Pharmacogenomics J 2003; 3: 17-26.
51. Darbari DS, van Schaik RH, Capparelli EV et al. UGT2B7 promoter variant 2840G.A contributes to the variability in hepatic clearance of morphine in patients with sickle cell disease. Am J Hematol 2008; 83: 200-2.
52. Levesque E, Delage R, Benoit-Biancamano MO et al. The impact of UGT1A8, UGT1A9, and UGT2B7 genetic polymorphisms on the pharmacokinetic profile of mycophenolic acid after a single oral dose in healthy volunteers. Clin Pharmacol Ther 2007; 81: 392-400.
53. Nakamura A, Nakajima M, Higashi E et al. Genetic polymorphisms in the 5′-flanking region of human UDP-glucuronosyltransferase 2B7 affect the Nrf2-dependent transcriptional regulation. Pharmacogenet Genomics 2008; 18: 709-20.
54. Court MH, Krishnaswamy S, Hao Q et al. Evaluation of 3′-azido-3′-deoxythymidine, morphine, and codeine as probe substrates for UDP-glucuronosyltransferase 2B7 (UGT2B7) in human liver microsomes: specificity and influence of the UGT2B7*2 polymorphism. Drug Metab Dispos 2003; 31: 1125-33.